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ACANTHOSIS NIGRICANS – A CLINICOEPIDEMIOLOGICAL 
AND THERAPEUTIC COMPARISON STUDY 
ABSTRACT 
INTRODUCTION 
            Acanthosis nigricans is characterized by velvety, brownish black 
pigmentation of flexural areas. Acanthosis nigricans is considered as a marker of 
internal diseases like insulin resistance, diabetes, hypothyroidism, polycystic 
ovarian disease and rarely internal malignancies.  
AIMS AND OBJECTIVES 
The study aims to   
1) Study the epidemiology of Acanthosis Nigricans 
2) Find out associated common endocrinological diseases 
3) Compare the effectiveness of various topical therapeutic modalities 
MATERIALS AND METHODS 
               Hundred patients of acanthosis nigricans were selected. Relevant 
investigations like blood sugar, fasting lipid profile, thyroid profile and ultrasound 
abdomen were done. Body mass index was calculated for all patients. Patients 
were then randomly divided into 5 treatment groups of 20 patients each. Group A 
receiving Topical 0.05% tretinoin, Group B receiving topical 0.005% calcipotriol, 
Group C receiving topical triple combination cream containing Hydroquinone 2%, 
tretinoin 0.05% and Fluocinolone acetonide 0.01%, Group D treated with 35% 
Trichloroacetic acid peel and Group E  treated with 50% Glycolic acid peel. 
OBSERVATION AND RESULTS 
               Acanthosis nigricans was more common in females than males with a 
ratio of 2.22: 1 and the mean age was 22.24 years. Nearly seventy percent of 
patients had abnormal body mass index. Acrochordon was the most common 
associated dermatological finding. Diabetes was the most common endocrine 
abnormality present in 41% of patients followed by dyslipidemia and 
hypothyroidism. Nearly 19% of the female patients had polycystic ovarian disease. 
Chemical peeling with trichloro acetic acid had the maximum response percentage 
of 75% and topical calcipotriol had the least response percentage of 25%. 
CONCLUSION 
  In our study age, sex and site distribution were in concurrence with the 
previous studies. Topical treatment need to be given for longer period with 
simultaneous treatment of endocrine disorders and obesity for better results. 
KEY WORDS 
         Acanthosis nigricans, insulin resistance and poly cystic ovarian disease. 
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INTRODUCTION 
 
 Acanthosis nigricans (AN) is classically considered as a cutaneous 
marker of systemic disease.1 
 
It is a common dermatological abnormality seen in numerous 
endocrine disorders like diabetes mellitus, insulin resistance, 
hypothyroidism, polycystic ovarian disease as well as internal 
malignancies.2 
 
Clinically acanthosis nigricans present as poorly marginated, 
hyperkeratotic, verrucous plaques with velvety texture and brownish-
black pigmentation.3  
 
  Lesions are symmetrically distributed over flexural areas which 
include axillae, nape and sides of neck, groin, and antecubital and 
popliteal areas. On occasion, the eruption may become almost 
generalized and also may involve mucosa.4 
 
This study was undertaken to know the epidemiology like age, sex 
distribution of Acanthosis Nigricans, various associated endocrinological 
diseases, and association of Acanthosis Nigricans with other cutaneous 
diseases and effectiveness of various topical treatments. 
  
Review of Literature 
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REVIEW OF LITERATURE 
        Acanthosis nigricans was coined by Unna which literally means 
black thorn. The Word acanthosis was derived from Greek meaning thorn 
and nigricans from Latin meaning black.5 
        Pollitzer, Unna’s student reported the first case in 1890. In the same 
year, Janovsky also described the first case.6 
        Curth clinically classified Acanthosis Nigricans as benign, 
malignant, syndromic and pseudo-acanthosis nigricans.7 
Schwartz in 1994 classified Acanthosis Nigricans into eight types 8 
1. Acral 
2. Benign 
3. Malignant 
4. Medication induced 
5. Obesity associated 
6. Syndromic 
7. Unilateral  
8. Mixed type  
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PREVALENCE 
The prevalence in general population is not known. Prevalence of 
Acanthosis Nigricans has been increasing recently due to the rising 
prevalence of obesity and Diabetes observed recently. It ranges from 7% 
to 74%, according to age, race, degree of obesity and concomitant 
endocrinopathy. Hud et al. demonstrated that prevalence among black 
women was higher compared to white women.9 
In India only few studies with prevalence in certain subpopulations 
are available. In a study conducted at Kerala in 2008, 16.1 % of 3069 
adults aged more than 18 years were found to have acanthosis nigricans. 
Prevalence among females was significantly higher (19.6%) than males 
(11.4%) and it was highest in 30-40 year age group. Obesity, high 
triglyceride levels and presence of diabetes correlated positively with 
prevalence of Acanthosis Nigricans.10 
In a study conducted at tertiary referral hospital in north India in 
2004 among 150 diabetics and 150 non diabetic matched controls the 
prevalence of Acanthosis Nigricans was 62.6% and 40% in subjects with 
diabetes and healthy controls respectively. The severity of Acanthosis 
Nigricans was found to increase with increasing BMI, waist-hip ratio, 
skinfold thickness, and body fat percentage in diabetic patients.11 
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SIGNIFICANCE 
Obesity and insulin resistance are linked to most cases of 
Acanthosis Nigricans. In diabetes Acanthosis nigricans is probably the 
most readily recognized skin manifestation.12 
 
         Acanthosis Nigricans may be considered as a predictor for type 2 
diabetes years before onset of other symptoms of diabetes mellitus.13 
 
          Clustering of several risk factors constitutes metabolic syndrome 
which includes central obesity, glucose intolerance, hyperinsulinemia, 
low HDL cholesterol, high triglycerides and hypertension. Metabolic 
syndrome is associated with five-fold greater risk of developing type 2 
diabetes and is also a risk factor for mortality due to cardiovascular 
disease. Acanthosis nigricans has high specificity and good sensitivity as 
a marker for metabolic syndrome.14 
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AETIOPATHOGENESIS 
            The central role in pathogenesis of Acanthosis nigricans is played 
by Insulin. 
Genetic predisposition  
           Benign acanthosis nigricans and unilateral or nevoid acanthosis 
nigricans follows an autosomal dominant inheritance with variable 
penetrance. 
Hyperinsulinemia  
         Insulin in addition to its metabolic effects has growth promoting 
action also. At low concentrations insulin binds to insulin receptors which 
have metabolic activity and weak growth promotion activity. At high 
concentrations insulin binds to IGF-1 R (insulin like growth factor 
receptor -1) which has more potent growth promoting effect. IGF-1 
receptors are expressed in basal keratinocytes and fibroblasts and excess 
insulin acting through these receptors causes epidermal and fibroblast 
proliferation leading to acanthosis nigricans. 12, 15  
          Normally IGF is bound to IGF binding proteins (IGFBP). In obese 
patients with hyperinsulinemia IGFBP levels are decreased leading to 
increase in concentration of free Insulin like Growth Factor that leads to 
increased cell growth and differentiation.15, 16 
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CLINICAL FEATURES  
Clinical morphology is the same for various types though it may 
vary in severity and distribution. Acanthosis Nigricans usually begins as 
grey brown or black pigmentation with dryness and roughness of the skin 
which later becomes palpably thickened. Later small papillomatous 
elevations arise from thickened skin giving rise to velvety texture. With 
further thickening skin markings become accentuated and surface 
becomes mammilated or rugose. Often asymptomatic, it may be 
occasionally pruritic. Mostly symmetrically distributed affecting 
commonly back and sides of neck, axillae, groin, and antecubital and 
popliteal areas in the order of decreasing frequency.15 
 
Neck is the most common area affected.  In children with 
acanthosis nigricans neck involvement is seen in 99% of children 
compared to axilla 73%. 17 
 
In cases of malignancy associated acanthosis nigricans skin lesions 
may be generalized and mucosal involvement may be there.52 
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Burke et al proposed grading of acanthosis nigricans severity at neck. 18 
 Grade 0 – not visible on close inspection 
 Grade 1 – clearly visible on inspection but with indistinct extent 
 Grade 2 – lesions only at base of skull not extending to lateral 
margins 
 Grade 3 – lesions extending to sides of neck but not visible on front 
of neck 
 Grade 4 – lesions extending to front of neck  
 
Neck texture 19 
0 - Smooth to touch: no differentiation from normal skin to palpation, 
1 - Rough to touch: clearly differentiated from normal skin 
2 - Coarseness can be observed visually, portions of the skin clearly rose 
above other areas 
3 - Extremely coarse: “hills and valleys” observable on visual 
examination  
 
Insulin resistance (IR)  
A metabolic disorder characterized by failure of target cells to 
respond to normal levels of circulating insulin resulting in compensatory 
hyperinsulinemia. It is especially found in individuals with type 2 
diabetes mellitus and obesity. Insulin resistance occurs in 20 to 25% of 
the normal individuals. 
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Insulin resistance is of 3 types:  
(i) Type A, characterized by reduction and dysfunction of insulin 
receptors  
(ii) Type B, produced by antibodies against insulin receptors  
(iii) Type C is a post-receptor defect.  
 
 Obese patients and patients with polycystic ovary syndrome 
(PCOS) have type-A insulin resistance.20 
 
Higher grades of acanthosis nigricans on the neck and axilla are 
sensitive markers for Insulin resistance and can be used as a clinical 
surrogate for assessment of severity of insulin resistance. It is better 
marker of insulin resistance than the traditionally used markers. 21, 22 
 
Insulin Resistance, whatever may its cause, stimulates insulin 
secretion and the excess insulin level stimulates IGF-1 receptors on 
various tissues including skin, where stimulation of the IGF - 1 receptors 
on keratinocytes lead to excessive epidermal growth.23 
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HISTOPATHOLOGY 24, 25 
Histopathology of typical cutaneous Acanthosis nigricans lesions 
shows following characteristic findings 
 Hyperkeratosis  
 Papillomatosis resulting from the finger-like upward projection of 
dermal papillae which are covered by thinned epidermis  
 ‘Valleys’ between these papillary projections showing mild 
canthosis with overlying hyperkeratosis. Acanthosis is only mild 
and irregular.  
11 
 
 Pigmentation of the lesions result primarily from the 
hyperkeratosis, though there is minimal hyperpigmentation of the 
basal layers.  
 
 Thus acanthosis nigricans is a misnomer as there is neither 
prominent acanthosis nor hypermelanosis in histology. 
 
 
 
Histopathological differential diagnosis 24, 25 
1. Linear verrucous epidermal nevus 
2. Seborrheic keratosis – hyperkeratotic type 
3. Verruca vulgaris 
4. Acrokeratosis verruciformis of Hopf 
5. Acanthosis nigricans type of mycosis fungoides 
 All these conditions are characterized by hyperkeratosis, acanthosis 
and papillomatosis. 
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TYPES OF ACANTHOSIS NIGRICANS 
Obesity-associated Acanthosis Nigricans 
It is the most common type of acanthosis nigricans - once called 
pseudo acanthosis nigricans. It is more common in adulthood, though 
lesions may appear at any age. Severity of the lesion is weight dependent 
and with weight reduction acanthosis nigricans lesions may completely 
regress. Often Insulin resistance is present.17 
 
Benign acanthosis nigricans 
 This rare genodermatosis may be present at birth or in early 
childhood and have a familial pattern. It is inherited as an autosomal 
dominant trait with variable phenotypic penetrance. It usually increases 
until puberty, after which it remains stationary or decreases. Obesity is 
not a factor.26, 27, 8 
 
Benign acanthosis nigricans has predilection for axilla and often 
there is exacerbation at puberty. They are not reversible with weight 
reduction unlike obesity associated type. 26 
 
Syndromic Acanthosis Nigricans  
 Acanthosis Nigricans when associated with a syndrome is called 
syndromic acanthosis nigricans. 
 
13 
 
 In addition to insulin resistance, acanthosis nigricans has been 
associated with numerous syndromes. Following 2 types are special 
examples 
 
1. Type A syndrome and 
2. Type B syndrome.  
 
The type A syndrome also termed as HAIR-AN syndrome 
presenting with hyperandrogenemia, insulin resistance and acanthosis 
nigricans syndrome. Primarily affecting young women this syndrome is 
often familial. It is associated with polycystic ovaries or signs of 
virilization. The lesions of acanthosis nigricans may arise during infancy 
and progress rapidly during puberty. 
 
The type B syndrome commonly occurs in women who have 
uncontrolled diabetes mellitus, ovarian hyperandrogenism, or an 
autoimmune disease such as systemic lupus erythematosus, scleroderma, 
Sjögrensyndrome, or Hashimoto thyroiditis. Circulating antibodies to the 
insulin receptor may be present. Here severity of acanthosis nigricans 
varies.17, 28, 29 
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Other Syndromes associated with acanthosis nigricans 8, 9 
1. Polycystic ovarian syndrome 
2. Cushing syndrome 
3. Down syndrome 
4. Bloom syndrome 
5. Costello syndrome 
6. Marfan syndrome 
7. Hirschowitz syndrome 
8. Capozucca syndrome 
9. Hermansky-Pudlack syndrome 
10. Kabuki syndrome 
11. Rud syndrome 
12. Prader-Willi syndrome 
13. Alstrom syndrome 
14. Rabson-Mendenhall syndrome 
15. Hypogonadal syndrome 
16. Acral hypertrophy syndrome 
17. Ataxia telangiectasia 
18. Crouzon’s syndrome  
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Polycystic ovary syndrome 17, 55 
 Polycystic ovary syndrome (PCOS) is one of the most common 
endocrine disorders in women affecting 5-10% of reproductive aged 
women. It is characterized by hyperinsulinemia and raised androgen 
levels.  
 
 Presence of significant number of the following criteria was 
considered in diagnosing PCOS 
 History of anovulation and/or menstrual irregularities 
 Hirsutism and/or temporal balding, oily skin and acne vulgaris 
 Elevated serum-free testosterone and/or elevated luteinizing 
hormone/follicle-stimulating hormone (LH/FSH) ratio and  
 Ultrasonographic finding of polycystic ovaries 
 
 The PCOS has number of dermatologic manifestations of 
hyperandrogenism like hirsutism, acne vulgaris and androgenetic 
alopecia. Acanthosis nigricans, a cutaneous sign of hyperinsulinemia may 
also be present. These findings provide early clinical clues to recognition 
of PCOS and treatment of these cutaneous conditions may improve the 
patient's quality of life and psychologic well-being.  
 
 Treatment modalities mainly include hormonal therapy.  
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Metabolic diseases with acanthosis nigricans 
1. Addison’s disease 
2. Hypothyroidism 
3. Primary biliary cirrhosis 
4. Hirsutism 
5. Acromegaly 
6. Gigantism 
7. Pseudoacromegaly 
8. Lipoatrophic diabetes 
9. Leprechaunism 
 
Nevoid Acanthosis Nigricans 29                           
Also known as Unilateral acanthosis nigricans, it is a rare form 
inherited as an irregularly autosomal dominant trait that first becomes 
evident at birth, in childhood, or during puberty. It is not associated with 
syndromes, drugs, endocrinopathies, or malignancies. After enlarging for 
a certain period it either remains stationary or starts regressing.  
 
 It resembles naevus unuis lateralis which is characterized by 
unilateral dry keratosis, presence of palmoplantar keratoderma and 
summer improvement.5 
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Acral Acanthosis Nigricans 8 
 Common in dark-skinned people it is characterized by velvety 
hyperkeratosis of the dorsum of the hands and feet. Generally health of 
these persons will be good.  
 
Malignant Acanthosis Nigricans  
  Acanthosis nigricans may be associated with many kinds of 
internal cancers, the most common being gastric adenocarcinoma. It is the 
most worrisome of the variants of acanthosis nigricans. It is differentiated 
from benign types by its sudden onset, presence of symptoms, more 
extensive involvement and atypical locations. Malignant acanthosis 
nigricans regresses with treatment of the underlying malignancy and 
reappears following recurrence or metastasis of the primary tumor.30 
 
Malignant acanthosis nigricans is a result of tumor cell expression 
of peptides that enhance cellular proliferation including transforming 
growth factor and epidermal growth factor. These factors secreted by the 
tumor binds to epidermal growth factor receptors and this in turn 
activates the Akt intracellular signaling pathway known to be involved in 
keratinocyte proliferation and epidermal thickening.31,32 
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MALIGANANT ACANTHOSIS NIGRICANS 
 
 
 
 
 
Binds to Epidermal Growth Factor 
(EGF) receptor on Basal 
Epidermal Cells 
Proliferation and Differentiation 
of Keratinocytes 
Acanthosis Nigricans 
Raised Serum TGF – α 
structurally similar to EGF - α 
Tumor Secreting Transforming 
Growth Factor – α (TGF – α) 
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 Malignant acanthosis nigricans is most commonly associated with 
gastrointestinal adenocarcinomas particularly gastric carcinoma. Other 
malignancies are those involving bronchus, bile duct, ovary, pancreas, 
gall bladder, endometrium, thyroid and breast. 33, 34, 35, 36 
 
Tripe palms: 
           Hyperkeratosis of the palms and soles (tylosis) along with 
involvement of the flexor surfaces of the fingers and toes, roughening and 
thickening of the fingerprints with prominence of the creases and a 
yellow hue may occur with malignancy associated acanthosis nigricans. 
This epidermal thickening may be exuberant and produce a rugose 
appearance with deep sulci labeled "tripe palms."  Mucosal involvement 
tend to be more common with malignant acanthosis nigricans.8 
 
Drug Induced Acanthosis Nigricans 
          It is a rare and reversible type of acanthosis nigricans.  Certain 
drugs act at cell receptor level and produce acanthosis nigricans. 
Mechanism of occurrence of this type of acanthosis nigricans is due to 
induction of a temporary state of insulin resistance which in turn 
produces acanthosis nigricans. Subcutaneous insulin injection causes 
localized acanthosis nigricans.37 
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Common drugs implicated are 
 Systemic corticosteroids 
 Nicotinic acid 
 Estrogens such as diethylstilbestrol 
 Insulin 
 Triazinate – folic acid antagonist 
 Methyltestosterone 
 Oral contraceptives 
 Fusidic acid 
 A melanocyte-stimulating hormone preparation composed of a 
crude extract of bovine pituitaries has been found to induce 
Acanthosis Nigricans 38, 39, 40, 41, 42 
 
Mixed-type Acanthosis Nigricans 
 When a patient with one of the above types of acanthosis nigricans 
develops new lesions of a different etiology, it is called Mixed-type 
acanthosis nigricans. Patient with obesity-associated acanthosis nigricans 
subsequently developing malignant acanthosis nigricans is an example.17  
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Differential diagnosis 
A. Cutaneous acanthosis nigricans 8, 9 
1. Confluent and reticulated papillomatosis – Presents as skin 
coloured or erythematous or hyperpigmented macular lesions over 
intermammary and upper lateral trunk.  
2. Intertriginous granular parakeratosis - Presents as erythematous to        
brownish hyperkeratotic papules and plaques in the intertriginous 
regions and is seen in middle aged women in axillae, but inguinal 
and submammary folds may be involved. 
3. Haber syndrome - Characterized by rosacea like facial dermatoses 
and multiple verrucous lesions on non-sun-exposed skin. 
4. Dowling - Degos disease also known as reticulate pigmented 
anomaly of the flexures is a familial nevoid condition presenting 
with progressive brown black hyperpigmentation of the flexures. 
There will be associated follicular hyperkeratosis. 
5. Acropigmentation reticularis of Kitamura - Presents as freckle like 
areas of pigmentation on the dorsal aspects of hands later involving 
other areas of body. Palmar pits and breakage of epidermal ridge 
pattern are also present. 
6. Nevus unuis lateralis sometimes resembles unilateral acanthosis 
nigricans. 
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7. Ichthyosis hystrix, melanocytic naevi, Becker’s nevus, Pellagra, 
hemochromatosis, or Addison's disease are other differential 
diagnosis 
 
B. Oral Mucosal acanthosis nigricans 8, 9 
 Mucosal involvement occurs frequently in malignant type of 
Acanthosis nigricans. 
 
Following are the differential diagnosis for mucosal acanthosis nigricans 
1. Cowden’s disease 
2. Dyskeratosis congenita 
3. Pyostamitis vegetans 
4. Pachyonychia congenita 
5. Wegener’s Granulomatosis 
 
TREATMENT OF ACANTHOSIS NIGRICANS 
 Main goal of therapy is to correct the underlying condition. There 
is no treatment of choice and no randomized controlled studies regarding 
treatment of acanthosis nigricans is available. Improvement of skin 
condition is patient’s main concern and the treatment is mainly for 
cosmetic purpose only. 9, 17 
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          Exercise and weight reduction increases the sensitivity to insulin 
and reduces hyperkeratotic lesions. Removal or replacement of offending 
drug leads to improvement in drug induced acanthosis nigricans .9, 17 
 
 In cases of malignancy associated acanthosis nigricans treatment 
and removal of underlying malignancy leads to improvement.32, 33 
 
Various topical and systemic agents are tried  
TOPICAL DRUGS 2, 9 
1. Tretinoin 
2. Calcipotriol      
3. Triple cream containing tretinoin 0.05%, hydroquinone 4% and 
fluocinolone acetonide 0.01%  
4. Combinations of tretinoin cream with 12% ammonium lactate 
cream, 
5. Podophyllin, urea and salicylic acid are tried with limited 
success 
 
SYSTEMIC DRUGS 2, 9, 16, 53 
1. Oral retinoids like acitretin or isotretinoin. Acitretin in an initial 
dose of 50mg followed by maintanence dose of 25 mg was used 
with some success. The mechanism of action is probably 
normalization of epithelial growth and differentiation 
24 
 
 
2. Metformin and rosiglitazone are useful in Acanthosis nigricans 
characterized by insulin resistance. Metformin and thiazolidines 
acts by increasing peripheral sensitivity to insulin. 
3. Oral octreotide has also been used with moderate success. 
Octreotide is a synthetic analog of the hypothalamic hormone 
somatostatin. Octreotide has a higher affinity for inhibition of 
glucagon, growth hormone, and insulin release compared with 
somatostatin. Octreotide 50 μcg  was used subcutaneously 3 
times daily. It acts by decreasing insulin secretion. 
4. Fish oil containing omega-3 fatty acids has been found to 
effectively reduce hyperpigmentation and normalized skin 
texture in a patient with acanthosis nigricans. 
 
LASER 8,60 
 Long-pulsed lasers have been tried. Recently, long-pulsed 
alexandrite laser was used to successfully treat acanthosis nigricans of the 
axilla. They act by causing photothermolysis. 
 
SURGICAL PROCEDURES 57 
          Dermabrasion involves removal of skin layers with either manual 
or motorized abraders. This wound is allowed to heal by secondary 
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intention so that a resurfacing effect will occur. Dermabrasion has been 
used with success for acanthosis nigricans. 
    
TRETINOIN 43, 44, 45, 46 
 Tretinoin - all-trans retinol represents an oxidized form of all-trans 
retinol is a naturally occurring retinoid.  
 
       
Mechanism of action 
 Transcription of genes that affects growth and differentiation of cells 
in the skin  
 Normalization of follicular epithelial differentiation and 
keratinization  
 
 In acanthosis nigricans it acts by producing comedolysis and also 
have palliative effects on fine wrinkling, mottled hyperpigmentation, and 
roughness of skin. 
 
 All-trans retinoic acid binds to cytosolic all-trans retinoic acid-
binding protein (CRABP). CRABP II is predominant in human skin and 
is the determining factor in the bioavailability of retinoids. Then it is 
transported to the nucleus by CRABP type II, where it binds to nuclear 
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retinoic acid receptors (RAR) and fatty acid-binding protein 5 (FABP5) 
and serves as a ligand for peroxisome proliferator-activated receptor β/δ 
(PPAR β/δ).  
 
Drug–RAR complexes subsequently binds to retinoic acid response 
elements (RARE), which are gene transcription enhancing elements 
leading to inhibition of cell growth. All-trans retinoic acid isomerizes to 
form 9-cis retinoic acid which binds to retinoid X receptors (RXR). RAR 
and RXR bind together as heterodimers to function as transcription 
factors. A number of all-trans retinoic acid responsive genes have been 
identified including  
 
1) type I epidermal transglutaminase, 
2) CRBP, 
3) CRABP,  
4) RAR and 
5) PPAR β/δ. 
 
Tretinoin also reduces the release of certain inflammatory mediators, 
including interleukins 1β, -6, -12, TNF-α, and IFN-γ. 
 Irritation and erythema are the common side effects. 
 They are category C pregnancy drugs.  
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CALCIPOTRIOL 47, 48 
 Calcipotriol is a synthetic vitamin D analog.  In skin it acts by 
binding to vitamin D3 receptors present in keratinocytes, melanocytes, 
dermal fibroblasts and many other cell types. Drug – receptor complex in 
association with retinoid X receptor RXR binds to vitamin D 3 responsive 
elements. 
 
 
 
 It acts by inhibiting cell proliferation and induces terminal 
differentiation in human keratinocytes. This reduction in number of 
keratinocytes minimizes the effects of excess insulin. In addition it has 
anti-inflammatory and immune modulatory action through inhibition of 
IL-2 and IL-6 production by T cells. It also has inhibitory action over 
cytotoxic T cells and NK cells. Thus skin conditions characterized by 
hyperkeratosis, acanthosis and hyper proliferation like psoriasis and 
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acanthosis nigricans can be treated with topical calcipotriol. It is used as 
0.005% cream. Side effects include erythema, hypercalcemia and 
irritation.  
 
TOPICAL TRIPLE CREAM 49, 54, 55 
 A triple combination cream containing tretinoin, 0.05%, 
hydroquinone 4%, and fluocinolone acetonide 0.01% was tried recently 
for treatment of Acanthosis nigricans. 
 
Effectiveness depends on the following actions  
1) Tretinoin 0.05% 
Normalization of epidermal turn over 
2) Hydroquinone 2% 
 
 
 
 Hydroquinone also known as 1, 4-dihydroxybenzene. It is an active 
agent that reduces melanocyte pigment production through degradation of 
melanin by auto-oxidation, tyrosinase inhibition, and formation of highly 
reactive oxygen radicals like semiquinones and quinones. These reactive 
substances prevent melanin production.   
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3) Fluocinolone acetonide 0.01% 49,54 
 
 
   
 Fluocinolone acetonide is an high potent topical corticosteroid 
(TCS) that acts by many ways. 
 
Mechanism of action 
TCS elicit their effects via binding to and activating GCR as follows 
1) The corticosteroid diffuses into the target cell and binds to the 
GCR in the cytoplasm. 
2) The corticosteroid-GCR complex undergoes necessary 
conformational changes. 
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3) The resulting active complex traverses the nuclear envelope and 
directly or indirectly binds to DNA. 
4) Gene regulation and transcription of various specific messenger 
ribonucleic acid (mRNA) occur. 
 
GCR are nearly ubiquitously expressed in human cells. TCS 
produce a myriad of actions. Both positive and negative gene regulation 
occurs.  Negative gene regulation has been associated with anti-
inflammatory action whereas positive gene regulation has been associated 
with some adverse effects.  
 
In acanthosis nigricans , topical corticosteroid  
 Decreases Number of keratinocyte mitoses  
 Reduces Stratum corneum thickness  
 Flattens basal layer keratinocytes  
 Suppression of Keratinocyte growth factors 
 Inhibition of Melanocyte pigment production  
 Reduces the irritation due to retinoid. 
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CS – GCR undergoes 
conformational change 
Traverses the nuclear envelope 
and Binds to DNA 
Regulation of genes and 
transcription of various mRNA 
Binds to Glucocorticoid Receptor 
in the cytoplasm (GCR) 
TCS diffuses into target cell 
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CHEMICAL PEELING 50 
Chemical peeling agents act by causing controlled destruction of 
skin followed by regeneration and remodeling of skin without scarring. 
 
Glycolic Acid 50 
 
 
Glycolic acid is an alpha hydroxic acid. It has lytic action on 
corneodesmosomes causing exfoliation and reduction of stratum corneum 
thickness. In the dermis it causes stimulation of fibroblasts and synthesis 
of glycosaminoglycans, collagen and elastin. A faint erythema is the end 
point.  As they are not self-neutralizing they need to be neutralized with a 
solution saturated with sodium bicarbonate.  
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Trichloroacetic Acid 51 
 
 
 
Trichloroacetic acid acts by causing coagulation of proteins which 
is seen as frosting. It doesn’t need any specific neutralizer as TCA is 
neutralized by serum in deep dermal vasculature. Concentration of TCA 
determines the depth of peel. Inflammation and activation of wound 
repair mechanisms follow coagulation leading to reepithelialization with 
replacement by smoother skin with even tone.  
 
 
 
 
 
 
 
Aims & Objectives 
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AIMS AND OBJECTIVES 
 
The study aims to   
1) Study the epidemiology of Acanthosis Nigricans 
2) To find out associated common endocrinological diseases 
3) To compare the effectiveness of various topical therapeutic 
modalities 
 
  
Materials and Methods 
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MATERIALS AND METHODS 
 
For the present study 100 cases of Acanthosis nigricans were 
randomly selected from the outpatient clinic in the Department of 
Dermatology, Rajiv Gandhi Government General Hospital, Chennai from 
October 2014 to august 2015. The study was started after obtaining 
approval from Institutional Ethical Committee. 
 
STUDY DESIGN     - Prospective study 
 
SUBJECT SELECTION 
Inclusion Criteria 
1. All patients presented with clinical features of acanthosis 
nigricans in dermatology outpatient department were selected. 
2. All patients who were willing to participate in study. 
 
Exclusion Criteria  
1. Patients who were already treated or undergoing other modes of 
treatment for Acanthosis nigricans. 
2. Patients who were not willing to participate in the study. 
 
 The diagnosis was based on clinical history and morphology of 
lesions. The selected patients were clearly explained about the natural 
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course of the disease, the possible benefits and side effects of treatment. 
Informed written consent was obtained from all the participants before 
initiating treatment. 
 
All the patients are evaluated as follows 
1. History  
 Detailed case history of each patient with reference to the duration 
and course of the disease, obesity, diabetes, thyroid related illness, 
menstrual abnormalities, family history and recent drug intake were 
taken. 
 
2. General examination:  
 Height, weight and Body mass index were noted. Other general 
examination findings like anaemia, jaundice and lymphadenopathy were 
noted. 
 
3. Systemic examination 
 Examination of cardiovascular, respiratory, gastrointestinal and 
central nervous system was done for all patients. 
 
4. Dermatological Examination 
 Clinical features like sites of involvement, morphology of lesions, 
symmetry, and other associated systemic and cutaneous disorders were 
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noted. Initial grading of acanthosis nigricans is noted using Burke et al 
grading of Acanthosis nigricans severity. 
 
5. Investigations 
 Following investigations were done in all patients 
a. Thyroid function test 
b. Fasting and post prandial blood sugar 
c. Fasting lipid profile  
d. Complete Blood haemogram 
e. Peripheral smear 
f. Liver function tests   
g. Renal function tests  
h. USG abdomen for all female patients to rule out PCOD. 
 
         Those patients with associated endocrinological abnormalities were 
treated for endocrinological abnormalities and those who are obese were 
advised weight reduction strategies. 
 
         For treatment of Acanthosis nigricans patients were randomly 
divided into five groups with 20 patients in each group.  
 
 Group A    - Topical 0.05% tretinoin 
 Group B    - Topical 0.005% calcipotriol. 
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 Group C    - Topical triple combination cream containing 
Hydroquinone 2%,  Tretinoin 0.05% and Fluocinolone acetonide 
0.01% 
 Group D           -  Chemical peeling with 35% Trichloroacetic acid 
 Group E            -  Chemical peeling with 50% Glycolic acid  
 
1. Group A 
 Twenty patients were randomly selected. After completing 
preliminary investigations these patients were treated with topical 0.05% 
tretinoin. Patients were advised to apply it daily once overnight for a 
period of 12 weeks. 
 
2. Group B  
 Twenty patients were randomly selected. After completing 
preliminary investigations these patients were treated with topical 0.005% 
calcipotriol. Patients were advised to apply it daily once overnight for a 
period of 12 weeks 
 
3. Group C  
 Twenty patients were randomly selected. After completing       
preliminary investigations these patients are treated with topical triple 
combination cream containing Hydroquinone 2%,  
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 Tretinoin 0.05% and Fluocinolone acetonide 0.01%. Patients were 
advised to apply it daily once overnight for a period of 12 weeks 
 
4. Group D 
 Twenty patients were randomly selected. After completing   
preliminary investigations these patients were treated with chemical 
peeling with 35% Trichloroacetic acid at 3 weekly intervals for a total 
period of 12 weeks. 
 
5. Group E 
 Twenty patients were randomly selected. After completing 
preliminary investigations these patients were treated with chemical 
peeling with 50% Glycolic acid at 3 weekly intervals for a total period of 
12 weeks. 
 
 All the patients are followed up at the interval of 3 weeks and at the 
end of 12 weeks, grading of acanthosis nigricans is again noted using 
Burke et al grading of Acanthosis nigricans severity.     
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STATISTICAL ANALYSIS:  
 The collected data was entered for analysis in Microsoft Excel. 
This data was exported to Statistical Package for Social Sciences software 
(SPSS) version 21. Mean, standard deviations and range were employed 
to describe continuous variables, while frequency distributions were 
obtained for dichotomous variables. Associations between qualitative 
variables were done using Chi square tests, Fisher’s exact test. A P value 
of less than 0.05 has been considered to be significant. 
 
  
Observations & Results 
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OBSERVATION AND RESULTS 
 
Table :1  AGE DISTRIBUTION OF  OF ACANTHOSIS 
NIGRICANS 
SI.No Age Group in Years Male Female 
Total No.Of 
Cases 
1 1 to 10 2 1 3 
2 11 to 20 14 37 51 
3 21 to 30 7 17 24 
4 31 to 40 5 9 14 
5 41 to 50 2 3 5 
6 51 to 60 1 2 3 
Total  31 69 100 
 
The most common age group in this study was 11 to 20 years 
Figure: 1 SEX DISTRIBUTION 
 
 
 In our study the number of female patients of Acanthosis Nigricans 
outnumbers the number of male patients.  
Female to male ratio was 2.22: 1. 
Male
31%
Female
69%
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Figure: 2 SITE DISTRIBUTION OF  
ACANTHOSIS NIGRICANS 
 
 
 
 Neck was the most common site in this study with 100% of 
patients showing neck involvement. Next to neck axilla is the second 
common site involved. 
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Table : 2 BODY MASS INDEX (BMI) DISTRIBUTION 
BMI in kg/m2 Male Female Total 
< 20 3 4 7 
20 - 24.99 9 14 23 
25 - 29.99 12 31 43 
≥ 30 7 20 27 
Total 31 69 100 
 
Body Mass Index is calculated by using the formula weight in kilograms/ 
height in meter square. 
BMI between 25 and 29.99 denotes overweight. 
BMI more than or equal to 30 indicates obesity.  
In this study 43% of patients were overweight and 27% of patients were 
obese. 
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Figure: 3 BMI DISTRIBUTIONS 
 
 
            
Figure: 4 ASSOCIATED OTHER DERMATOLOGICAL DISEASES 
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 All patients with acanthosis nigricans were screened for other 
dermatological diseases and the following findings were observed. 
 
Acrochordon            – 35 
Acne Vulgaris               –  9 
Pityriasis versicolor               – 4 
Acne vulgaris and Acrochordon    – 3 
Seborrheic dermatitis       – 3 
Dermatophyte infection       – 2 
Polymorphous light eruption      – 2  
Psoriasis             – 1 
Nil         – 41 
 
 In this study acrochordon was the most common associated 
dermatological finding which was found in 38% of our patients followed 
by Acne vulgaris which was found in 12% of patients. 
 
 In this study 41% of patients had only acanthosis nigricans without 
any other associated dermatological disease. 
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ENDOCRINE TESTS 
 
HYPOTHYROIDISM 
 
Table: 3 THYROID FUNCTION TEST 
 Normal Hypothyroid Percentage 
Male 20 11 35.48 
Female 48 21 30.43 
Total 68 32 32 
 
Figure: 5 THYROID FUNCTION TEST 
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DIABETES MELLITUS 
 
Table: 4 FASTING BLOOD SUGAR 
 Normal Increased Percentage 
Male 21 10 32.25 
Female 38 31 44.92 
Total 59 41 41 
 
Figure: 6 FASTING BLOOD SUGAR 
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DYSLIPIDEMIA 
Table 5: FASTING LIPID PROFILE 
 Normal Abnormal Percentage 
Male 22 9 29.03 
Female 44 25 36.23 
Total 66 34 34 
 
 In this study raised fasting blood sugar was the most common 
endocrine abnormality present in 41% of patients.  
 
 Next to diabetes mellitus abnormal fasting lipid profile was the 
common finding with 34% of patients having dyslipidemia. 
 
 Hypothyroidism was present in 32% of study patients. 
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FIGURE: 7 CONSOLIDATED ENDOCRINE FINDINGS 
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Figure: 8 ULTRASOUND ABDOMEN 
 
 
 
 In this study ultrasound abdomen was done for all female patients. 
Of the 69 females 13 females were having polycystic ovarian disease.  
Among the study patients, 18.84% of the females with acanthosis 
nigricans had associated polycystic ovarian disease. 
  
56
13
0
10
20
30
40
50
60
Normal PCOD
Co
un
t
51 
 
 
Figure: 9 PRE TREATMENT GRADING OF SEVERITY 
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Table: 6 SEX AND PRE TREATMENT GRADING 
 
Grade 
Male Female  
Total 
percentage Number % within Sex Number 
% within 
Sex 
1 5 16.1 5 7.2  10 
2 16 51.6 20 29  36 
3 6 19.4 30 43.5 36 
4 4 12.9 14 20.3 18 
Total 31 100 69 100 100 
 
In this study most of the patients presented with grade 2 or grade 3 each 
of which contributes to 36% of study population.  
Eighteen percentage of patients presented with grade 4 severity. 
Ten percentage of patients presented with grade 1 severity. 
Among the male patients of acanthosis nigricans Grade 2 was the 
commonest presentation which contributed to 51.16% of male patients. 
Among the female patients of acanthosis nigricans Grade 3 was the 
commonest presentation which contributed to 43.5% of female patients.  
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Figure: 10 SEVERITY GRADING DISTRIBUTION 
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Table: 7 RESPONSE PERCENTAGE OF DIFFERENT 
TREATMENTS 
Treatment Given Total No. 
No. Of 
Patients 
Responded 
% of 
Response 
 
P 
value 
Calcipotriol 20 5 25 
0.021 
Glycolic Acid peel 20 13 65 
TCA peel 20 15 75 
Tretinoin 20 11 55 
Triple cream 20 12 60 
 
Figure: 11 TREATMENT RESPONSE 
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 In this study decrease in severity grading from pretreatment  
grading after treatment was taken as presence of response and if there is 
no change in severity grading after treatment at the end of study period it 
was taken as no response.   
 
 In this study group of patients treated with Trichloroacetic acid 
chemical peeling had shown the highest response percentage with 75% of 
them showing response.  
 
 Chemical peeling with glycolic acid has shown the next highest 
response percentage with 65% of them showing response.  
 
 Patients who are treated with topical triple cream showed 60% 
response and those treated with topical tretinoin showed 55% response. 
 
 Topical treatment with daily application of calcipotriol has shown 
the least response percentage with only 25% of them was responding. 
Difference in treatment response found among the groups in this 
study was significant. (p value = 0.021) 
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Table: 8 SEX AND RESPONSE 
Sex Response No Response % of Response 
Male 17 14 54.83 
Female 39 30 56.52 
Total 56 44 56 
 
Figure: 12 SEX AND RESPONSE 
 
 
 In this study response percentage for both males and females were 
almost closer with females showing slightly higher response percentage. 
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Table: 9 PCOD AND RESPONSE RELATION 
PCOD Response Present No Response % of Response 
Present 5 8 38.46 
Absent 37 19 66.07 
 
Figure: 13 ULTRASOUND ABDOMEN AND RESPONSE 
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 In this study 13 female patients were found to have PCOD on 
ultrasound abdomen and pelvis screening and the treatment response 
percentage was 38.46. 
 
 In those female patients with normal ultrasound finding the 
response percentage was 66.07 which was higher than those with PCOD. 
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Table: 10 AGE DISTRIBUTION AND RESPONSE 
Age ( In Years) Response No Response Response Percentage 
< 10 2 1 66.66 
11 – 20 29 22 56.86 
21 – 30 14 10 58.33 
31 – 40 7 7 50 
41 – 50 2 3 40 
> 50 2 1 66.66 
 
 In this study even though patients with extremes of age group 
showed highest response percentage their count was very low to be taken 
as significant. 
 
 In age groups with adequate number of patients, highest response 
percentage was found in age group between 21 and 30 years. 
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Table: 11 BODY MASS INDEXAND RESPONSE 
BMI RESPONSE NO RESPONSE 
RESPONSE 
PERCENTAGE 
<25 21 9 70 
25 - 29.99 25 18 58.13 
≥ 30 10 17 37.03 
 
Figure: 14 BODY MASS INDEX AND RESPONSE 
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 In this study the treatment response rate for patients with body 
mass index less than 25 was 70%. 
 
 Those patients who were either overweight or obese with a body 
mass index more than 25 and less than 30 had a response percentage of 
58.13%. 
 
 Among patients with body mass index greater than or equal to 30 
the response percentage was 37.03%. 
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Image 1 and 2: ACRAL ACANTHOSIS NIGRICANS 
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Image 3: ACANTHOSIS NIGRICANS OF NECK WITH 
ACROCHORDON 
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Image 4: ACANTHOSIS NIGRICANS NECK GRADE 1 
 
 
 
Image 5: ACANTHOSIS NIGRICANS NECK GRADE 2 
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Image 6: ACANTHOSIS NIGRICANS NECK GRADE 3 
 
 
 
Image 7: ACANTHOSIS NIGRICANS NECK GRADE 4 
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Image 8 and 9: PRE AND POST TREATMENT WITH TRETINOIN 
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Image 10 and 11: PRE AND POST TREATMENT 
 WITH GLYCOLIC ACID 
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Image 12 and 13: PRE AND POST TREATMENT  
WITH TRIPLE CREAM 
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Image 14 and 15: PRE AND POST TREATMENT  
WITH TRICHLOROACETIC ACID 
  
Discussion 
  
70 
 
 
DISCUSSION 
 
Acanthosis Nigricans is a common dermatological disease which 
clinically present as hyperpigmented, hyperkeratotic, verrucous and 
velvety plaques seen commonly over neck, axilla and extremities. 
 
Acanthosis Nigricans may be a marker of internal diseases like 
insulin resistance, diabetes mellitus, dyslipidemia, hypothyroidism, 
polycystic ovarian disease and rarely internal malignancies like gastric 
carcinoma.  
 
Acanthosis Nigricans may also occur as a side effect of certain 
drugs and familial cases also been reported. 
 
In this study 100 patients of Acanthosis Nigricans were selected 
and divided randomly into 5 groups of 20 patients in each group. 
 
Sex Distribution 
          In this study the number of female patients with Acanthosis 
Nigricans outnumbered male patients with 69 females and 31 males. 
 
           In this study the ratio of female to male patient was 2.22: 1. 
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           This ratio was in concurrence with the previous studies by Neeraj 
Puri et al 17 which showed a female to male ratio of 3:2 and study by 
Varthakavi et al 23 which showed a female to male ratio of 3.5:1 
 
Age Distribution 
                In this study the most common age group was between 11 and 
20 years which contributed to about 51% of study population. Also the 
number of patients in extremes of age group was low with only 3% of 
patients were aged less than 10 years and another 3% were aged more 
than 50 years.            
 
               This was in concurrence with the previous studies by Neeraj 
Puri et al 17 where 33.3% of patients were in the age group between 11 to 
20 years contributing the highest age group percentage. Also 3.3% of 
patients were aged less than 10 years and 10 % were more than 50 years 
of age. 
 
              The mean age in our study was 22.24. This was slightly lower 
than the mean age of previous study by Varthakavi et al 23 where the 
mean age was 26.3. 
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Site Distribution of Acanthosis nigricans  
                In this study neck was the most common site involved with 
100% of patients showing neck involvement. Axilla was the second most 
common site with 63% involvement. 
 
 This was in concurrence with the previous study by Varthakavi et 
al 23 where neck involvement was 100% followed by axilla involvement 
in 80.6% of patients. 
 
Body Mass Index (BMI) 
 In this study 43% of patients were overweight and 27% of patients 
were obese with a BMI more than or equal to 25 kg/meter square. Thus in 
this study only 30% of patients were having normal BMI.          
 
Associated other Dermatological Diseases 
          Acrochordon was the most common associated dermatological 
condition present in 38 % of patients. This was followed by acne vulgaris 
which occurred in 12% of patients. 
 
 This was in concurrence with the study by Neeraj Puri et al 17 
where acrochordon was the commonest associated condition present in 
26.6% of patients. 
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Endocrine Dysfunction 
 In this study Diabetes was the commonest endocrine abnormality 
with 41% of patients showing raised fasting blood sugar.  
 
 Hypothyroidism was present in 32% of study patients and 
dyslipidemia was present in 34% of patients. 
 
 These results were in concurrence with the study by Varthakavi et 
al 23 where 44.4 % of patients were diabetic with either impaired glucose 
tolerance test or frankly diabetic profile. 
 
 In the study done by Neeraj Puri et al 17 diabetes was present in 
30% of patients and hypothyroidism was present in 13.3% of patients 
which was lower compared to our study. 
 
Poly Cystic Ovarian Disease 
 In this study on ultrasound screening PCOD was present in 18.84% 
of female patients with Acanthosis nigricans. 
 
 This observation was close to the observation in the study by 
Neeraj Puri et al 17 where 20% of females were having PCOD. 
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Pre Treatment Grading 
 In this study most Acanthosis Nigricans patients presented with 
either Grade 2 or grade 3 severity. 
 
 Among the male patients with acanthosis nigricans Grade 2 was 
the commonest presentation which contributed to 51.16% of male 
patients. 
 
 Among the female patients with acanthosis nigricans Grade 3 was 
the commonest presentation which contributed to 43.5% of female 
patients. 
 
Treatment Response comparison 
 In this study chemical peeling with trichloroacetic acid had highest 
response percentage of 75%. 
 
 Chemical peeling with glycolic acid had shown the next highest 
response percentage with 65% of them showing response.  
 
 Patients who are treated with topical triple cream showed 60% 
response and those treated with topical tretinoin showed 55% response. 
 
  Patients who were treated with daily application of calcipotriol had 
the least response percentage of 25%. 
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 Difference found among the treatment groups was statistically 
significant with a p value of 0.021. 
 
 Although some of the patients had shown significant improvement 
in severity with decrease in Grading from grade 4 to Grade 1, none of the 
patients showed complete clearance of lesion at the end of the study 
period. This may be due to shorter duration of treatment. Patients need to 
be followed up with continuous treatment for a longer period. 
 
Sex and Response 
 In this study response percentage was almost equal among males 
and females with 54.83% of males and 56.52% of females showing 
response to treatment. 
 
PCOD and Response 
 In this study the response percentage of female patients with 
PCOD was lower than the female patients without PCOD. Response 
percentage was 38.46% in female patients with acanthosis nigricans and 
66.07% in patients without acanthosis nigricans.  
 
 This observation indicates that patients with PCOD were more 
resistant to treatment and they may need longer period of treatment along 
with simultaneous treatment for correction of PCOD. 
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Body Mass Index and Response 
 In this study the response percentage was higher with those having 
BMI less than 25 kg/m2 and the response percentage was lowest with 
those having BMI more than or equal to 30 kg/m2 . 
 
 In this study the treatment response rate for patients with body 
mass index less than 25 was 70%. 
 
 Those patients who were either overweight or obese with a body 
mass index more than 25 and less than 30 had a response percentage of 
58.13%. 
 
 Among patients with body mass index greater than or equal to 30 
the response percentage was 37.03% 
 
 Thus in this study response rate decreases with increasing body 
mass index. 
 
  
Conclusion 
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CONCLUSION 
 
 Acanthosis Nigricans was more common in females as compared to 
males. 
 The most common age group at presentation was 11to 20 years. 
 The most common site of involvement of acanthosis nigricans was 
neck followed by axilla. 
 Most patients with acanthosis nigricans in this study had associated 
obesity with 70% of population falling under either overweight or 
obese according to body mass index value. 
 Acanthosis nigricans was associated with several endocrine diseases 
with 42% of study population having raised fasting blood sugar, 32% 
of patients having hypothyroidism and 34% of patients showing 
dyslipidemia. 
 Polycystic ovarian disease was present in 18.84% of female patients 
with acanthosis nigricans. 
 Most patients of acanthosis nigricans presented with either grade 2 
or grade 3 severity with males presenting with lower grade than 
females. 
78 
 
 Treatment response was almost similar among both male and female 
patients with an average response percentage of 56. 
 Patients treated with trichloroacetic acid chemical peeling had the 
best response percentage while patients treated with topical 
calcipotriol had the least response percentage.  
 Patients treated with glycolic acid chemical peeling, topical tretinoin 
and topical triple cream had intermediate response percentage. 
 None of the treatment modalities used in this study was effective in 
completely clearing acanthosis nigricans skin lesions. This may be 
due to shorter treatment period of 12 weeks. 
 Patients with polycystic ovarian disease showed less response to 
treatment compared to those with normal ultrasound finding. It 
suggests the importance of simultaneous treatment of associated 
polycystic ovarian disease. 
 Response of patients to treatment decreases with increasing body 
mass index. It suggests the need for weight reduction for better 
treatment results. 
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Annexures 
 
                                     ABBREVIATIONS USED 
AN   – Acanthosis nigricans 
IGF-1 R  – Insulin like growth factor 1 receptor 
IGFBP  – Insulin like growth factor binding proteins 
HDL   – High density lipoprotein 
BMI   – Body mass index 
PCOS  – Polycystic ovarian syndrome 
HAIR-AN – Hyperandrogenism, Insulin resistance and  
   Acanthosis Nigricans  
TGF- α  – Transforming Growth Factor α 
EGF   – Epidermal Growth Factor 
CRABP  – cytosolic all-trans retinoic acid-binding protein  
RAR   – Retinoic acid receptors  
RARE  – Retinoic acid response elements  
RXR   – Retinoid X receptors  
TNF-α  – Tumor necrosis factor α  
 IFN-γ  – Interferon γ. 
TCS   – Topical corticosteroid 
GCR   – Glucocorticoid receptor 
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Pre 
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Post 
Treatment 
Grading 
Respo
nse 
1 M 23 3 N,AX 26.8 ACRO N + N - Tretinoin 2 1 R 
2 F 13 3 N,AX 26.1 - HT - N N TCA peel 3 1 R 
3 F 24 4 N,AX 23.1 - N - AB N Triple cream 4 2 R 
4 M 15 2 N 31.2 ACNE HT - AB - Tretinoin 2 2 NR 
5 F 17 5 N,AX 36.3 ACRO N - AB PCOS Calcipotriol 3 3 NR 
6 F 11 3 N 31.1 - HT - N N Triple cream 2 1 R 
7 F 37 6 N,AX 27.3 TV N - AB N Calcipotriol 2 2 NR 
8 M 12 2 N,AX 21.3 - N - N - Tretinoin 3 2 R 
9 M 11 3 N,AX 22.4 - HT - AB - Calcipotriol 2 1 R 
10 F 47 6 N,AX 26.3 ACRO N + N N Tretinoin 1 1 NR 
11 F 15 1 N 32.3 - N + AB PCOS TCA peel 4 2 R 
12 M 36 5 N,AX 32.2 ACRO HT - N - Triple cream 2 2 NR 
13 F 14 3 N 25.8 - N + AB N Glycolic Acid peel 3 1 R 
14 F 13 2 N,AX 18.6 - HT - N N Tretinoin 2 1 R 
15 F 34 4 N,AX 22.5 ACRO N + N N TCA peel 4 2 R 
16 M 24 3 N,AX 23.1 TV N + N - Triple cream 1 1 NR 
17 F 55 5 N,AX 24.3 - N - N N Tretinoin 3 2 R 
18 F 19 7 N,AX,AC 31.4 ACRO HT + AB PCOS TCA peel 3 3 NR 
19 F 14 3 N,AX 25.3 ACNE N - N N Calcipotriol 2 2 NR 
20 M 22 4 N,AC 19.2 ACRO N - N - Triple cream 2 1 R 
21 F 19 3 N,AX 23.2 SD N + N N Tretinoin 2 1 R 
22 F 33 2 N,AX 24.5 - HT + N N Glycolic Acid peel 3 3 NR 
23 M 8 3 N,AX 30.4 - N + AB - TCA peel 2 2 NR 
24 F 23 4 N,AX 32.5 ACRO HT + N PCOS Triple cream 3 3 NR 
25 F 12 2 N,AX 26.3 - N - N N Glycolic Acid peel 3 2 R 
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26 F 15 5 N,AX,AC 27.8 ACNE N - N N Calcipotriol 3 3 NR 
27 M 42 3 N,AX 25.8 TV HT + N - Calcipotriol 2 2 NR 
28 F 15 3 N,AX 29.1 TINEA N - N N Triple cream 2 1 R 
29 F 17 5 N,AC 33.5 ACRO HT + AB N Tretinoin 3 3 NR 
30 F 11 3 N,AX 26.1 TV N - N N TCA peel 2 1 R 
31 M 16 3 N,AX 24.3 SD N - N - Glycolic Acid peel 4 2 R 
32 F 35 3 N 24.1 - N + N N Triple cream 1 1 NR 
33 F 12 2 N 27.7 - N - N N Tretinoin 3 2 R 
34 M 37 4 N,AC 27.3 - HT - N - TCA peel 2 1 R 
35 F 25 3 N,AX 35.3 ACRO N + AB PCOS Glycolic Acid peel 2 2 NR 
36 M 15 2 N,AX 28.1 ACNE N - AB - Triple cream 3 2 R 
37 F 18 1 N,AX 19.6 ACRO + ACNE N - N N Tretinoin 2 2 NR 
38 F 18 5 N,AX 34.1 ACRO HT + N N TCA peel 4 2 R 
39 M 23 5 N,AX 36.3 ACRO HT + N - Glycolic Acid peel 2 1 R 
40 F 13 3 N 26.8 - N + N N Calcipotriol 2 2 NR 
41 F 33 5 N,AX 31.3 ACRO N + N PCOS Tretinoin 4 4 NR 
42 F 20 3 N,AX 36.4 PLE N - AB N Triple cream 4 2 R 
43 M 13 1 N 28 - HT - AB - TCA peel 3 1 R 
44 F 19 3 N,AX 31.3 ACRO N - AB N Glycolic Acid peel 2 2 NR 
45 M 33 4 N,AX 19.6 PSORIASIS HT - N - Glycolic Acid peel 2 1 R 
46 F 37 6 N,AX 21.4 - N - N N Calcipotriol 4 3 R 
47 M 19 4 N 31.3 ACRO HT + N - Triple cream 2 2 NR 
48 F 13 1 N,AX 32.3 ACNE N - AB N Tretinoin 2 2 NR 
49 F 12 3 N,AX 19.2 - N - N N TCA peel 3 1 R 
50 F 31 3 N,AX 28.3 ACRO N + AB PCOS Triple cream 3 2 R 
51 M 14 2 N,AX 28.6 - N + N - Tretinoin 3 2 R 
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52 M 35 2 N,AX 22.6 - N - N - Calcipotriol 2 2 NR 
53 F 32 2 N,AC 23.1 - N + N N Glycolic Acid peel 3 1 R 
54 F 17 3 N,AX 33.4 ACRO HT - AB N Glycolic Acid peel 4 2 R 
55 F 11 1 N 22.3 - N - N N TCA peel 4 1 R 
56 M 7 2 N,AX 21.7 - N - N - Glycolic Acid peel 3 1 R 
57 F 24 3 N,AX 28.9 - HT + N N Tretinoin 3 2 R 
58 F 43 4 N,AX 26.1 ACRO N - AB N Triple cream 2 1 R 
59 F 27 5 N 31.7 ACRO N + AB N Calcipotriol 3 2 R 
60 M 13 1 N 30.4 - N + AB - TCA peel 2 1 R 
61 F 18 5 N 27.3 ACRO HT + N N Glycolic Acid peel 1 1 NR 
62 F 13 5 N,AX 24.1 ACNE N - N N Glycolic Acid peel 3 2 R 
63 F 25 5 N,AX 25.2 ACRO N + N PCOS Tretinoin 2 2 NR 
64 M 43 5 N,AC 35.6 ACRO HT - N - Triple cream 1 1 NR 
65 F 29 5 N,AX 23.5 - N - N N Calcipotriol 1 1 NR 
66 F 12 3 N 25.7 - N + N N TCA peel 2 2 NR 
67 F 15 3 N,AX 35.4 - N - AB N Calcipotriol 3 3 NR 
68 M 12 3 N 22.5 - HT + N - Tretinoin 1 1 NR 
69 F 25 2 N,AC 26.3 ACRO + ACNE N - AB N Triple cream 2 1 R 
70 F 20 2 N,AX 26.9 ACRO HT - N N Glycolic Acid peel 4 2 R 
71 M 23 2 N,AX 18.2 ACRO N - N - TCA peel 4 1 R 
72 F 39 4 N 18.3 - N - N N Glycolic Acid peel 2 1 R 
73 F 23 3 N,AX 30.6 ACRO N + AB PCOS Calcipotriol 3 3 NR 
74 F 19 3 N 22.5 ACNE N - N N Triple cream 2 1 R 
75 F 27 4 N 25.4 ACRO N + N PCOS TCA peel 3 2 R 
76 M 54 8 N 29.4 ACRO HT - AB - Calcipotriol 1 1 NR 
77 M 24 4 N,AX 24.8 PLE N - AB - Glycolic Acid peel 3 2 R 
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78 F 51 10 N 25.3 ACRO N - N N TCA peel 3 1 R 
79 F 22 3 N 36.3 ACRO HT + N N Calcipotriol 3 2 R 
80 F 21 2 N,AX 27.4 SD N - N N Glycolic Acid peel 1 1 NR 
81 F 20 3 N,AX 34.3 ACRO HT - N N Triple cream 2 2 NR 
82 F 24 4 N 26.3 - N + AB PCOS Tretinoin 3 2 R 
83 M 33 3 N 22.6 ACRO N - N - TCA peel 1 1 NR 
84 F 17 3 N,AX 31.8 ACRO N + AB PCOS Glycolic Acid peel 3 3 NR 
85 F 18 2 N 26.2 - HT + AB N Calcipotriol 2 2 NR 
86 F 48 6 N 25.9 ACRO N - N N Triple cream 4 3 R 
87 M 17 3 N 28.1 - HT - N - Tretinoin 2 2 NR 
88 M 13 2 N 25.4 ACNE N - N - Calcipotriol 2 1 R 
89 F 23 3 N,AX 21.3 TINEA HT - N N TCA peel 3 3 NR 
90 F 9 2 N,AX 20.9 - N - N N Tretinoin 3 2 R 
91 F 13 3 N,AX 28.6 - HT - N N Calcipotriol 4 4 NR 
92 M 12 3 N,AX 26.3 - N + AB - Glycolic Acid peel 4 2 R 
93 M 27 4 N,AX 26.9 ACRO + ACNE N - N - Triple cream 2 2 NR 
94 F 14 2 N 29.3 - N + AB N TCA peel 3 1 R 
95 F 23 3 N 26.5 ACNE HT - N N Glycolic Acid peel 4 4 NR 
96 F 15 3 N,AX 27.1 - N + AB N Calcipotriol 3 3 NR 
97 F 13 2 N 36.1 - N + AB N Tretinoin 4 3 R 
98 F 25 3 N,AX 26.9 ACRO N - N N Triple cream 3 2 R 
99 M 11 1 N 27.3 - HT - N - Calcipotriol 4 4 NR 
100 F 18 2 N,AX 28.3 ACRO N + AB PCOS TCA peel 3 2 R 
 
  
KEY FOR MASTER CHART 
 
SEX 
        M  - MALE  
        F   - FEMALE 
 
DISTRIBUTION 
       N   - NECK 
       AX  - AXILLA 
       AC  - ACRAL 
 
BMI  – BODY MASS INDEX IN WEIGHT IN KILOGRAMS /  
  HEIGHT IN METER SQUARE 
 
OTHER CUTANEOUS LESION 
       ACRO - ACROCHORDON 
       PLE  - POLYMORPHOUS LIGHT ERUPTION 
       SD  - SEBORRHEIC DERMATITIS 
       TV - TINEA VERSICOLOR 
       TINEA  - TINEA CORPORIS 
       PSORA - PSORIASIS VULGARIS 
 
THYROID FUNCTION TEST 
      HT  - HYPOTHYROID 
      N   - NORMAL 
       
DM - DIABETES MELLITUS 
 
FASTING LIPID PROFILE 
      AB  - ABNORMAL 
      N   - NORMAL 
 
USG ABDOMEN 
      PCOS - POLY CYSTIC OVARIAN SYNDROME 
      N   - NORMAL 
 
TREATMENT GIVEN 
 TCA PEEL – TRICHLOROACETIC ACID PEEL 
 
RESPONSE 
      R  - RESPONDED 
      NR  - NO RESPONSE 
  
PROFORMA 
  
Case No: 
 
PATIENT DETAILS: 
 
 
Name:                                                    Age:            Sex:              OP No: 
 
 
Address:                                                Occupation: 
 
 
Main Complaints: 
             
 
 
H/O present illness;  
            Duration of illness 
            Sites involved 
            Progression 
 
    
H/O of increased frequency of micturition, increased appetite 
H/O gain or loss of weight 
H/O altered bowel habits, intolerance to heat and cold 
H/O abdominal pain, melena 
H/O breathlessness, chest pain, chronic cough 
H/O drug intake for any chronic illness                                             
 
Family History:   
 
Marital/menstrual History: 
 
 
Associated dermatological disorders:      Acne 
                                                                 Skin tag. 
                                                                 Seborrhoeic dermatitis 
                                                                 other dermatological conditions 
CLINICAL EXAMINATION: 
General examination :     Height 
                                                               Weight 
                                                               Body Mass Index 
Generalised lymphadenopathhy                                                        
Pulse:                BP: 
RR:            Temp: 
Pallor:         Icterus: 
CVS:        RS: 
P/A:      
CNS 
 
 Bones and joints 
 
 
DERMATOLOGICAL EXAMINATION: 
 
Site of involvement:  Nape of neck/ axilla/ groin/ extremities 
 
Pretreatment severity Grading: 
       
 Palms and soles: 
 Oral and genital Mucosa: 
 Hair and nail: 
 
Investigations 
 
1. Blood haemogram 
2. Blood sugar fasting and postprandial 
3. RFT 
4. LFT 
5. Blood lipid profile 
6. Fasting serum insulin level. 
7. Thyroid function test 
8. USG abdomen 
TREATMENT: 
Group: 
Regimen given:  
 
FOLLOW UP: 
Complaints 
  
Grading  
 
Side effects   
 
  
INFORMATION SHEET 
 
TITLE :  “ACANTHOSIS NIGRICANS – A CLINICOEPIDEMIOLOGICAL  
  AND THERAPEUTIC COMPARISON STUDY” 
 
Name of Investigator: Dr.E.Balasubramanian    
 
Name of Participant: 
 
Purpose of Research: The purpose of this study is to determine the clinical 
profile, common associated endocrinological disorder and comparing treatment 
options in patients with Acanthosis nigricans. 
 
Study Procedures:  In this study history of patient will be taken, 
examination and routine blood test will be taken, endocrinological evaluation 
will be done. The patients are then randomly grouped into 5 groups of 20 
numbers each  
 
Group A    - Topical 0.05% tretinoin daily application 
Group B    - Topical 0.005% calcipotriol daily application. 
Group C    - Topical triple combination cream containing Hydroquinone 2%,  
Tretinoin 0.05% and Fluocinolone Acetonide 0.01% daily 
application 
Group D    - Chemical peeling with 35% Trichloroacetic acid once in every  
   3 weeks 
Group E     - Chemical peeling with 50% Glycolic acid once in every 3 weekss 
. 
Possible Risks : No risks to the patient 
 
Possible benefits  
To patient: Any underlying endocrinological problems will be detected and the 
patient is provided with any of the above mentioned treatments for his primary 
complaint. 
 
To doctor & to other people:  The results of the study will help in identifying 
the commonest endocrinological diseases associated with acanthosis nigricans 
patients and also to determine the most effective treatment for acanthosis 
nigricans. This will help in providing better and complete treatment to other 
patients in future. 
  
 
Confidentiality of the information obtained from you: The privacy of the 
patients in the research will be maintained throughout the study. In the event of 
any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 
Can you decide to stop participating in the study: Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to 
withdraw at any time 
 
How will your decision to not participate in the study affect you: Your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
 
 
 
Signature of Investigator                Signature of Participant 
 
Date : 
Place : 
  
                                     PATIENT CONSENT FORM 
 
Title of the study:   
ACANTHOSIS NIGRICANS – A CLINICOEPIDEMIOLOGICAL 
AND THERAPEUTIC COMPARISON STUDY 
 
Name of the Principal investigator: Dr.E.Balasubramanian. 
 
 Name of the Institution: Rajiv Gandhi Government General Hospital, Chennai 
 
  Patient’s Name :  
  Patient’s Age :  
  Out Patient No  :  
 
Patient may check (☑) these boxes 
 I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction. 
 
 I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
 
 I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study.  
 I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms.  
I hereby consent to participate in this study 
 
 
 
 I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests and to undergo 
treatment  
 
 
Signature/thumb impression    Signature of Investigator 
Signature/thumb impression     Study Investigator’s Name: 
 
  
   

    

 
